To alleviate regulatory barriers in Medicare and Medicaid, Centers for Medicare & Medicaid Services (CMS) may engage in more pay-for-performance or outcomes-based payment schemes similar to the Novartis arrangement for their $475,000 leukemia drug, Kymriah.
In this arrangement, CMS will only be liable for payment if the drug works.
For more on this and future drug-pay schemes, click here.
(Source: InsideHealthPolicy.com, paid subscription required).
